Ads
related to: sglt2 inhibitor adverse effects list
Search results
Results From The WOW.Com Content Network
Dapagliflozin is an example of an SGLT-2 inhibitor, it is a competitive, highly selective inhibitor of SGLT. It acts via selective and potent inhibition of SGLT-2, and its activity is based on each patient's underlying blood sugar control and kidney function. The results are decreased kidney reabsorption of glucose, glucosuria effect increases ...
It is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. [1] It is taken by mouth. [1] The most common side effect is genital infection in women. [2] Other common side effects include diabetic ketoacidosis, diarrhea, and genital infection in men. [2]
Canagliflozin is indicated to be used with diet and exercise to lower blood sugar in adults with type 2 diabetes; to reduce the risk of major heart-related events such as heart attack, stroke, or death in people with type 2 diabetes who have known heart disease; and to reduce the risk of end-stage kidney disease, worsening of kidney function, heart-related death, and being hospitalized for ...
Other diabetes drugs, specifically sodium-glucose cotransporter 2 (SGLT2) inhibitors, can also lead to a reduction in lean mass. This includes canagliflozin (Invokana®) and dapagliflozin (Farxiga®).
Dapagliflozin is used along with diet, exercise, and usually with other glucose-lowering medications, to improve glycaemic control in adults with type 2 diabetes. . Dapagliflozin, in addition to other SGLT2-inhibitors, was shown to reduce the rate of decline in kidney function and kidney failure in non-diabetic and type 2 diabetic adults when added to the existing treatment
A new study has found a combination of an SGLT-2 inhibitor drug and a moderately calorie-restrictive diet provides higher rates of type 2 diabetes remission compared to just calorie restriction alone.
Empagliflozin is an inhibitor of the sodium glucose co-transporter-2 (SGLT-2), and works by increasing sugar loss in urine. [2] Empagliflozin was approved for medical use in the United States and in the European Union in 2014. [13] [23] [24] It is on the World Health Organization's List of Essential Medicines. [25]
GLP-1 analogs resulted in weight loss and had more gastrointestinal side-effects, while in general dipeptidyl peptidase-4 (DPP-4) inhibitors were weight-neutral and are associated with increased risk for infection and headache. Both classes appear to present an alternative to other antidiabetic drugs.
Ad
related to: sglt2 inhibitor adverse effects list